Affordable Access

Access to the full text

A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients

Authors
  • Wang, Biyun1
  • Zhao, Yannan1, 2
  • Li, Yi1, 2
  • Xu, Yingying2
  • Chen, Yun3
  • Jiang, Qiuyu2, 4
  • Yao, Dingjin2
  • Zhang, Li2
  • Hu, Xichun1
  • Fu, Chaowei3
  • Zhang, Si2
  • Chen, She2
  • 1 Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, 270 Dong’an Road, Xuhui District, Shanghai, 200032, China , Shanghai (China)
  • 2 Fudan University, 130 Dong’an Road, Xuhui District, Shanghai, 200032, China , Shanghai (China)
  • 3 Fudan University, Shanghai, China , Shanghai (China)
  • 4 Shanghai Institute of Liver Diseases, Zhongshan Hospital, Fudan University, Shanghai, China , Shanghai (China)
Type
Published Article
Journal
Molecular Cancer
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Jan 18, 2022
Volume
21
Issue
1
Identifiers
DOI: 10.1186/s12943-022-01504-0
Source
Springer Nature
Keywords
Disciplines
  • Liquid Biopsy at the Frontier of Early Detection, Prognosis and Cancer Treatments
License
Green
Report this publication

Statistics

Seen <100 times